Author：XLIFESC
Release date：2024-04-10
On the afternoon of April 8, 2024, XlifeSc ("XLifeSc") presented a new T-cell immunotherapy method at the 115th American Association for Cancer Research (AACR) Annual Meeting through an academic poster, bringing new hope to T-cell therapy for cancer.
The AACR Annual Meeting is one of the most prestigious and long-standing conferences dedicated to cancer research globally. The 115th AACR Annual Meeting opened grandly on April 5, 2024, in San Diego, attracting over 22,500 professionals worldwide. The conference, themed "Inspiring Science·Advancing Progress·Innovating Therapies," gathered top experts and scholars in the field of oncology to discuss early cancer research and innovative advancements.
Abstract Title：A new strategy for T cell therapy: T cells secreting TCR anti-CD3 bispecific T-cell engager
Session Category：Clinical Research
Session Title：Adoptive Cellular Therapy 1
Presentation Abstract Number：#3598
XLifeSc has innovatively developed a new T-cell therapy called TCE-T. This therapy involves T cells secreting bispecific T-cell engager molecules composed of TCR and CD3 antibodies in the body to treat tumors. This approach cleverly integrates the advantages of TCR-T and TCE technologies, ensuring long-term durability of the treatment while effectively recruiting bystander T cells, significantly enhancing the immune response and reducing the amount of T-cell infusion required.
The study targeted alpha-fetoprotein (AFP) as a precise target, successfully constructing TCE-T cells targeting liver cancer cells. Experiments have shown that these cells can accurately and efficiently kill AFP-positive and HLA A0201-positive liver cancer cells. Using advanced genetic engineering, we successfully enabled T cells to secrete bispecific TCR-CD3 antibody T-cell engagers, which activate both infused T cells and bystander T cells to collectively kill liver cancer cells. This innovative measure significantly enhances the anti-tumor activity of T cells.
TCE-T therapy brings new hope to the field of cancer treatment, broadening therapeutic strategies and providing a potentially effective personalized treatment method for many patients. We hope this therapy can bring blessings to more cancer patients in the future, helping them overcome the disease and regain their health.
About XlifeSc
XlifeSc Technology (Guangdong) Co., Ltd. ("XlifeSc", "XLifeSc") is a leading company focused on the development of TCR field cell immunotherapy products and technologies. XlifeSc is dedicated to the research and development, clinical translation, and exploration of cutting-edge technologies in T-cell immunotherapy products.
XlifeSc has an experienced and rigorous R&D team with independent intellectual property rights for core TCR technology and a complete TCR-T product R&D and manufacturing system. The TCR-T product R&D system includes: ① Antigen Peptide Discovery Platform, ② High-Affinity TCR Platform, and ③ TCR-T Development Platform. The TCR-T manufacturing system includes: ① Automated Cell Production Platform and ② Quality Control Platform. The company has established a full-chain innovation industry chain for TCR-T cell products.
Currently, XlifeSc has two investigational products approved by the National Medical Products Administration (NMPA) for clinical research. The first product, TAEST16001, is the first TCR-T cell therapy product in China to receive IND approval, with the first indication being advanced soft tissue sarcoma, which has entered Phase II clinical trials with smooth progress. Other indications are also under development. The second product, TAEST1901, with the first indication being primary liver cancer, is initiating Phase I clinical research.
XlifeSc' TCR-T pipelines are extensive, covering a wide range of targets, including CT antigens, neoantigens, and viral antigens related to tumors. The products cover multiple HLA genotypes prevalent in the Chinese population, such as A0201, A1101, and A2402, and the indications include various clinically challenging solid tumors.
